PD-012Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type metastatic colorectal cancer (mCRC): A retrospective analysis of three panitumumab studies

Introduction: Systemic therapy with epidermal growth factor receptor (EGFR) inhibitors ± chemotherapy can result in tumour shrinkage in patients with wild-type (WT) RAS mCRC, potentially facilitating curative surgery. Treatment decisions should be guided in part by patients’ disease symptoms, yet there is no standardised assessment of symptomatic events. This retrospective analysis aimed to investigate whether ETS is related to the time to occurrence of new tumour-related symptoms during first-line treatment of mCRC.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research